92976 Federal Register / Vol. 89, No. 227 / Monday, November 25, 2024 / Notices 

the requestor is a lineal descendant or 

a culturally affiliated Indian Tribe or 

Native Hawaiian organization. 

Repatriation of the cultural items in 

this notice to a requestor may occur on 

or after December 26, 2024. If competing 

requests for repatriation are received, 

the Museum of Us must determine the 

most appropriate requestor prior to 

repatriation. Requests for joint 

repatriation of the cultural items are 

considered a single request and not 

competing requests. The Museum of Us 

is responsible for sending a copy of this 

notice to the Indian Tribes and Native 

Hawaiian organizations identified in 

this notice and to any other consulting 

parties. 

Authority: Native American Graves 

Protection and Repatriation Act, 25 

U.S.C. 3004 and the implementing 

regulations, 43 CFR 10.9. 

Dated: November 18, 2024. 

Melanie O’Brien, 

Manager, National NAGPRA Program. 

[FR Doc. 2024–27514 Filed 11–22–24; 8:45 am] 

BILLING CODE 4312–52–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1411] 

Certain Photodynamic Therapy 

Systems, Components Thereof, and 

Pharmaceutical Products Used in 

Combination With the Same; Notice of 

Commission Determination Not To 

Review an Initial Determination 

Granting in Part Complainant’s Motion 

To Amend the Complaint and Notice of 

Investigation 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the U.S. International Trade 

Commission has determined not to 

review an initial determination (‘‘ID’’) 

(Order No. 8) of the presiding 

administrative law judge (‘‘ALJ’’) issued 

in the above-captioned investigation, 

granting in part complainant’s motion to 

amend the complaint and notice of 

investigation (‘‘NOI’’) to add 

infringement allegations as to claims 17 

and 18 of U.S. Patent No. 11,446,512 

(‘‘the ’512 patent’’). 

FOR FURTHER INFORMATION CONTACT: 

Richard P. Hadorn, Esq., Office of the 

General Counsel, U.S. International 

Trade Commission, 500 E Street SW, 

Washington, DC 20436, telephone (202) 

205–3179. Copies of non-confidential 

documents filed in connection with this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. General 

information concerning the Commission 

may also be obtained by accessing its 

internet server at https://www.usitc.gov. 

Hearing-impaired persons are advised 

that information on this matter can be 

obtained by contacting the 

Commission’s TDD terminal, telephone 

(202) 205–1810. 

SUPPLEMENTARY INFORMATION: The 

Commission instituted this investigation 

on August 1, 2024, based on a complaint 

filed by Sun Pharmaceutical Industries, 

Inc. (‘‘Sun Pharma’’) of Princeton, New 

Jersey. 89 FR 62790 (Aug. 1, 2024). The 

complaint, as supplemented, alleges 

violations of section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 

1337, based on the importation into the 

United States, the sale for importation, 

and the sale within the United States 

after importation of certain 

photodynamic therapy systems, 

components thereof, and 

pharmaceutical products used in 

combination with the same by reason of 

infringement of certain claims of the 

’512 patent and U.S. Patent No. 

11,697,028 (‘‘the ’028 patent’’). Id. The 

complaint further alleges that a 

domestic industry exists or is in the 

process of being established. Id. The 

notice of investigation names four 

respondents: (1) Biofrontera Inc. of 

Woburn, Massachusetts; (2) Biofrontera 

Pharma GmbH of Leverkusen, Germany; 

(3) Biofrontera Bioscience GmbH of 

Leverkusen, Germany; and (4) 

Biofrontera AG of Leverkusen, Germany 

(collectively, ‘‘Biofrontera’’). Id. The 

Office of Unfair Import Investigations is 

not a party to this investigation. Id. 

On October 7, 2024, Sun Pharma filed 

a motion to amend the complaint and 

NOI to add infringement allegations as 

to claims 9, 11, 17, and 18 of the ’512 

patent and claims 10 and 12 of the ’028 

patent. On October 17, 2024, Biofrontera 

filed a response opposing-in-part the 

motion. Specifically, Biofrontera did not 

oppose the motion with respect to 

adding infringement allegations as to 

claims 17 and 18 of the ’512 patent, but 

opposed the remainder of the motion. 

On October 22, 2024, the ALJ issued 

the subject ID granting the motion in 

part. The ID finds that, in accordance 

with Commission Rule 210.14(b) (19 

CFR 210.14(b)), good cause exists for 

amending the complaint and NOI to add 

infringement allegations as to claims 17 

and 18 of the ’512 patent, noting that 

‘‘Biofrontera agrees that Sun Pharma’s 

allegations with respect to these claims 

are based on information obtained 

through discovery.’’ ID at 3. The ALJ, 

however, found that Sun Pharma has 

not shown the requisite good cause to 

amend the complaint and NOI to add 

infringement allegations as to claims 9 

and 11 of the ’512 patent and claims 10 

and 12 of the ’028 patent because ‘‘Sun 

Pharma failed to demonstrate why it 

was unable to bring the allegations [of 

those claims] in the complaint.’’ Id. at 

3–5. No petitions for review of the 

subject ID were filed. 

The Commission has determined not 

to review the subject ID. The complaint 

and NOI are amended to add 

infringement allegations as to claims 17 

and 18 of the ’512 patent. 

The Commission vote for this 

determination took place on November 

20, 2024. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: November 20, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–27568 Filed 11–22–24; 8:45 am] 

BILLING CODE 7020–02–P 

NUCLEAR REGULATORY 

COMMISSION 

[NRC–2024–0001] 

Sunshine Act Meetings 

TIME AND DATE: Weeks of November 25 

and December 2, 9, 16, 23, 30, 2024. The 

schedule for Commission meetings is 

subject to change on short notice. The 

NRC Commission Meeting Schedule can 

be found on the internet at: https://

www.nrc.gov/public-involve/publicmeetings/schedule.html. 

PLACE: The NRC provides reasonable 

accommodation to individuals with 

disabilities where appropriate. If you 

need a reasonable accommodation to 

participate in these public meetings or 

need this meeting notice or the 

transcript or other information from the 

public meetings in another format (e.g., 

braille, large print), please notify Anne 

Silk, NRC Disability Program Specialist, 

at 301–287–0745, by videophone at 

240–428–3217, or by email at 

Anne.Silk@nrc.gov. Determinations on 

requests for reasonable accommodation 

will be made on a case-by-case basis. 

STATUS: Public. 

Members of the public may request to 

receive the information in these notices 


khammond on DSK9W7S144PROD with NOTICES